Publications by authors named "Basil S Lewis"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

53,990

Total Likes

864

Extended Reach

568,217

Social Features

93
C
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Marc S Sabatine, Gaetano M De Ferrari, Robert P Giugliano, Kurt Huber, Basil S Lewis, Jorge Ferreira, Julia F Kuder, Sabina A Murphy, Stephen D Wiviott, Christopher E Kurtz

Circulation· August 2018

Videos about Article: user user

2 4 2 2

View All Article and Social Media Activity
E
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema

June 2015

Videos about Article: user user

2 59 87 9 53

View All Article and Social Media Activity
A
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.
Gianluigi Savarese, Felix Lindberg, Antonio Cannata, Marianna Adamo, Giuseppe Ambrosio, Basil S Lewis

Eur J Heart Fail· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC.
Gabriele Fragasso, Davide Stolfo, Markus S Anker, Antoni Bayes-Genis, Ovidiu Chioncel, Basil S Lewis

Eur J Heart Fail· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.
Yu Mi Kang, Robert P Giugliano, Xinhui Ran, Prakash Deedwania, Gaetano M De Ferrari, Basil S Lewis

Diabetes Care· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.
Davide Stolfo, Massimo Iacoviello, Ovidiu Chioncel, Markus S Anker, Antoni Bayes-Genis, Basil S Lewis

Eur J Heart Fail· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention.
Peter Jüni, Sotiris Antoniou, Elena Arbelo, Sergio Buccheri, Maja Cikes, Basil S Lewis

Eur Heart J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.
Sem A O F Rikken, C Michael Gibson, M Cecilia Bahit, Danielle Duffy, Gerald Chi, Basil S Lewis

JACC Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue.
Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial.
C Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, Gerald Chi, Harvey White, Basil S Lewis

Eur Heart J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.
Sneha S Jain, Kenneth W Mahaffey, Karen S Pieper, Wataru Shimizu, Tatjana Potpara, Basil S Lewis

Am Heart J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
Muhammad Shahzeb Khan, Javed Butler, Rebecca Young, Basil S Lewis, Jorge Escobedo

JACC Heart Fail· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis.
Paul M Haller, Niema Kazem, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
Thomas J Povsic, Serge Korjian, M Cecilia Bahit, Gerald Chi, Danielle Duffy, Basil S Lewis

J Am Coll Cardiol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
C Michael Gibson, Danielle Duffy, Serge Korjian, M Cecilia Bahit, Gerald Chi, Basil S Lewis

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
Massimo Imazio, Allan L Klein, Antonio Brucato, Antonio Abbate, Michael Arad, Basil S Lewis

J Am Heart Assoc· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA.
Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting.
Eri Toda Kato, Koh Ono, Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor XIa inhibitors: collecting the clinical evidence.
Basil S Lewis, Koji Hasegawa

Eur Heart J Cardiovasc Pharmacother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity.
Eri Toda Kato, Basil S Lewis, Koh Ono

Eur Heart J Cardiovasc Pharmacother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
Heinz Drexel, Juan Tamargo, Juan Carlos Kaski, Basil S Lewis, Christoph H Saely

Eur Heart J Cardiovasc Pharmacother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis.
Paul C Cremer, David Lin, Sushil A Luis, John Petersen, Antonio Abbate, Basil S Lewis

Eur Heart J Imaging Methods Pract· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
Antonio Brucato, Alistair Wheeler, Sushil Allen Luis, Antonio Abbate, Paul C Cremer, Basil S Lewis

Heart· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
John W Eikelboom, Jacqueline Bosch, Stuart J Connolly, Jessica Tyrwitt, Keith A A Fox, Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events.
Juan Tamargo, Juan Carlos Kaski, Takeshi Kimura, Jack Charles Barton, Ko Yamamoto, Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction?
Koji Hasegawa, Basil S Lewis

Eur Heart J Cardiovasc Pharmacother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.
Clara Saldarriaga, Dan Atar, Amanda Stebbins, Basil S Lewis, Imran Zainal Abidin

Eur J Heart Fail· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis